Crowdonomics
WatchlistPortfolio
Aspire BioPharma

Reg CF · Preferred Stock · Oct 2023

ClosedReached targetReg CFPreferred Equity
via Republic · last checked Oct 8, 2026View campaign
Raised
$226.8K / $5M max
5% of ceiling · target hit day 65
Investors
138
$1.6K avg
Post-money valuation
$352.2M
pre-money + amount raised

Raised over time

Cumulative raisedInvestors
$228K$114K$0
140700
Oct 28, 2023 · openedFeb 1, 2024 · last reading
Target ($150K) hit — Jan 1, 2024, day 65Deadline Jan 31, 2024

Left axis: cumulative dollars raised. Right axis: cumulative investors. Live figures via Republic, last checked Oct 8, 2026; investor counts may lag the platform by up to a day.

Financials disclosed in this offering

FY2021–FY2022 · hover for source
$0
−$464K
FY2021
$0
−$597K
FY2022
RevenueNet income
Metric
FY2021 audited
FY2022 audited
Income statement
Revenue
$0
$0
Cost of goods sold
$0
$0
Net income
-$464,173
-$597,117
Taxes paid
$626
$626
Balance sheet
Cash
$185,496
$38
Accounts receivable
$0
$0
Total assets
$185,496
$4,917,644
Short-term debt
$117,169
$193,881
Long-term debt
$0
$3,852,552
Total liabilities
$117,169
$4,046,433
Other
Headcount
—
0

The fiscal years the issuer disclosed in this offering’s filing, as filed. Full history on the company page.

Deal terms

Pre-money$352M
Post-money$352.2M
Price / share$0.80
Shares offered187,500

Offering details

Target$150,000
Max$5,000,000
Min investment$500
OpenedOct 28, 2023
DeadlineJan 31, 2024
ClosedJan 31, 2024
Days active95

Links & provenance

Campaign pageSEC filing
Source: Manual
0001995528-23-000001

About this data. Raised amounts and investor counts come from the platform listing and may lag or be restated; SEC-reported totals can differ until the next Form 1-Z/C-U. Post-money valuation is computed as pre-money plus amount raised and is shown once the round closes — it is not a traded price. Financial statements are as reported by the issuer. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.